-- 獨立研究機構CFRA向提供了以下研究報告。 CFRA分析師總結如下：淡水河谷第一季業績喜憂參半，調整後EBITDA為39億美元（年增21%），營收為93億美元（年增14%），但銷售額低於市場預期2.37億美元，調整後每股收益為0.44美元，低於預期0.06美元。儘管季節性支出對營運資金造成了不利影響，但自由現金流仍達到8.13億美元（年增61%）。基本金屬表現突出，EBITDA飆升至12億美元（年增116%），主要得益於銅EBITDA達到9.49億美元（年增74%），而銅的EBITDA成長則得益於市場供應緊張和價格上漲。管理階層表示，鑑於巴西雷亞爾兌美元升值，2026年的成本指引將趨向區間上限。鐵礦石利潤率面臨壓力，C1成本上漲至23.60美元/噸（年增12%），主要受匯率不利因素影響，但銷售仍維持堅挺，達5,940萬噸（年增5%）。資產負債表依然穩健，淨負債為136億美元，槓桿比率控制在過去12個月調整後EBITDA的0.8倍。我們認為，淡水河谷多元化的業務組合能夠提供韌性，其基本金屬業務的優勢將在短期內抵消鐵礦石利潤率的壓縮。
Related Articles
Research
Research Alert: Gsk Q1 Beat As Specialty Medicines Remains Strong, Reiterates 2026 Outlook
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:GSK delivered a Q1 2026 beat with sales growing 2% Y/Y (5% CER), led by Specialty Medicines (+10% or +14% CER), particularly oncology with strong Jemperli and Ojjaara uptake, while Vaccines grew 4% CER on record Shingrix sales. Core EPS grew 4% or 9% CER to GBP0.465, ahead of the consensus of GBP0.44, supported by a favorable product mix and cost control that lifted the core operating margin by 1.0%-pt or 1.8%-pts CER. We view the Q1 update positively given the beat and margin expansion, though we are mindful of currency headwinds. GSK reiterated its 2026 guidance for 3%-5% sales growth and 7%-9% core operating profit growth (CER), which is broadly aligned with that of several peers like Sanofi and Roche despite implying slower growth versus 2025. We expect revenue to be supported by key Specialty Medicines products, with GSK targeting the segment to contribute more than 50% of sales by 2031 (Q1 2026: 42%), while recent acquisitions provide a much-needed boost to growth and the drug pipeline, in our view.
$GSK
Asia
Gamuda Unit Bags Nearly MYR6 Billion Project from Sabah State Water Department
Gamuda (KLSE:GAMUDA) unit Upper Padas Power received a Letter of Acceptance worth 5.98 billion ringgit from the Sabah State Water Department for Phase 1 of the Skim Bekalan Air Ulu Padas.The project forms a bolt-on development linked to the Ulu Padas Hydroelectric Project and is designed to strengthen water supply for Sabah's west coast, according to a Wednesday Malaysian bourse filing.Phase 1 involves the construction of a 350 million litres per day water treatment plant in Beaufort, along with about 200km of pipelines stretching from Sipitang to Kota Kinabalu.The project marks a key infrastructure expansion alongside its hydroelectric development in Sabah, Malaysia, the company said.
$KLSE:GAMUDA
Equities
Aker Solutions to Develop Framed Modules Components for Rolls-Royce SMR
Aker Solutions (AKSO.OL) secured a deal to develop non-nuclear parts of framed modules for Rolls-Royce (RR.L) unit Rolls-Royce SMR, according to a Wednesday release.Under a memorandum of understanding, the Norwegian energy-focused engineering group will work with Rolls-Royce SMR to define the design and scope, and modularization approach for customer projects in the UK and other countries, with an initial focus on the UK and the Czech Republic.
$AKSO.OL$RR.L